Olink Investor Relations Material
Latest events
Q2 2023
Olink
Q1 2024
13 May, 2024
Q4 2023
25 Mar, 2024
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Olink Holding AB
Access all reports
Olink Holding AB develops and markets proteomics solutions for academic and pharmaceutical research. The company’s technology platform enables high-throughput protein biomarker discovery and validation. It serves customers in biomarker research, drug development, and diagnostics. The company is headquartered in Uppsala, Sweden, and its shares are listed on the NASDAQ.
Latest articles
)
The Dilemma That Brought Down Kodak
Kodak helped invent digital photography but failed to embrace it. How the innovator's dilemma turned an icon into its own most famous casualty.
21 Aug 2025
)
Maziar Mike Doustdar: Novo Nordisk's New CEO
A portrait of the pharmaceutical giant's new CEO, who assumes the position at a critical time for the company in its competition with Eli Lilly.
12 Aug 2025
)
Novo Nordisk: Tipping the Scale of Innovation
Taking a look at the company behind Ozempic and Wegovy and diving into their history, business, and the challenges it now faces
8 Aug 2025
Ticker symbol
OLK
Country
🇺🇸 United States